Kornimate/medical-research-clean huggingface dataset:
effect of percutaneous electrical nerve field stimulation on symptom control/nervous system activity in patients w/diabetes types 1/2

Conditions: Diabetes; Gastroparesis

Summary: the purpose of this study is to find out if we can stimulate the vagus nerve. the vagus nerve is a largely internal nerve that controls many bodily functions, including stomach function. we hope that electrically stimulating the nerve around the external ear will also stimulate the internal vagus nerve. if it does, then we hope that this will help our treatment of patients with nausea and vomiting and disordered stomach function.

each participant will be randomized to receive percutaneous electrical nerve field stimulation (penfs) treatment with or without stimulation. the study involves 6 study visits. study procedures include: removing and replacing the penfs device, questionnaires, ecg, assessment use of galvanic skin response (gsr), pneumatic belt to assess breathing, physical examine, and blood draws.

Eligibility criteria:
inclusion criteria: * wiling to have one teaspoon (5 ml) of blood drawn. * diagnosed with gastroparesis for twelve months or longer * diagnosed with diabetes either type 1 or type 2 * documented delayed gastric emptying (\>10% retention of the test meal at four hours) on a standardized scrambled-egg scintigraphy gastric emptying test performed in the last two years. * upper gi endoscopy indicating no mechanical obstruction performed in the last five years. * symptoms of nausea and vomiting consistent with clinical diagnosis of gastroparesis (as opposed to other causes of nausea and vomiting such as mechanical obstruction, acute viral illness, chemotherapy, psychogenic vomiting. * documented hb a1c within three months of screening or at the time of screening (\<=8.0) exclusion criteria: * unable to provide consent * pregnant females * medical records indicate intestinal pseudo-obstruction * diagnosed with cardiac arrhythmia * history of prior gastric surgery * history of vagotomy * history of organ transplantation * history of seizures * diagnosed with primary swallowing disorders * subjects who are dependent on drugs like marinol for their condition * those diagnosed with psychogenic vomiting and not related to gastroparesis * medically unstable subjects * those at high surgical risk * subjects taking narcotic analgesics daily. * those with poorly controlled diabetes mellitus (hgb a1c\>8) within three months of screening or at the time of screening. * subjects diagnosed with hemophilia, psoriasis vulgaris are excluded * those having a cardiac pacemaker will be excluded from the study.
blunt thoracic trauma: definition of a standard operating procedure

Conditions: Rib Fractures; Polytrauma; Thoracic Injury; Respiratory Failure

Summary: rib fractures are the most frequent injury after blunt thoracic trauma. it is very important to choose the most appropriate interventions to prevent complications. but who will benefit most of those interventions remains a challenge. this study analyses the correlation between chest x-ray and ct scan. we also analyse different scores to predict respiratory failure.


Eligibility criteria:
inclusion criteria: * polytrauma patients admitted to de icu with a thoracic ct scan in the first 24h of arrival exclusion criteria: * penetrating trauma * patients referred from other hospitals
the effect of automated electronic alert for acute kidney injury on the outcomes of hospitalized patients

Conditions: Acute Kidney Injury; Outcomes; Early Diagnosis

Summary: acute kidney injury (aki) is a common disease, but diagnosis is usually delayed or missed in hospitalized patients. the automated electronic alert for aki may help to improve the outcomes of these patients through identifying all cases of aki early. therefore, the investigators conduct a randomly controlled study to test whether automated electronic alert for aki could improve the outcomes of hospitalized patients.

acute kidney injury (aki) is a common disease, but diagnosis is usually delayed or missed in hospitalized patients. the automated electronic alert for aki may help to improve the outcomes of these patients through identifying all cases of aki early. therefore, the investigators conduct a randomly controlled study to test whether automated electronic alert for aki could improve the outcomes of hospitalized patients. the patients were randomly divided into two groups: usual care : patients will receive standard clinical care by the primary physicians aki alert : an aki alert will be sent to the doctor in charge. the team of kidney experts would give a suggestion if the doctor in charge need a renal consultation.

Eligibility criteria:
inclusion criteria: * hospitalized adult patients with an alert for aki(based on kdigo guidelines) exclusion criteria: * patients already having egfr\<15ml/min/1.73m2 or receiving renal replacement therapy for aki at the time of alert. * patients already having a aki before admission.
relationship between blood glucose variability and prognosis in critically ill patients

Conditions: Diabetes

Summary: this study is to evaluate the glycemic variation using continuous glucose monitoring system in patients in the intensive care unit, find out the occult hypoglycemia, and investigate the relationship between glycemic variation, especially the incidence of hypoglycemia and prognosis of patients. meanwhile, the inflammatory factors were measured and the relationship between inflammatory factors and glycemic variation.


Eligibility criteria:
inclusion criteria: 1. patients with history of diabetes; 2. patients without history of diabetes, but their random blood glucose≧7.8mmol/l or fast blood glucose≧5 mmol/l; 3. the patients hospitalized in care unit (icu or ccu) for more than 48 hours. exclusion criteria: 1. patient had history of mental illness; 2. patient was not suitable for using the cgms; 3. blood glucose \> 22.2 mmol/l at admission.
impact of predictive genetic testing

Conditions: Genetic Testing; Quality of Life; Physical Activity

Summary: analysing impact of preemptive genetic testing on quality of life, physical activity and eating behavior at baseline and 3 months after testing.


Eligibility criteria:
inclusion criteria: * age ≥18 years * informed consent for genetic testing * informed consent for study participation exclusion criteria: * age \<18 years * renal replacement dependency * pregnancy * active cancer disease * no informed consent for genetic testing or study participation
a one-year observation of palivizumab in infants at risk for respiratory syncytial virus infection in latin america

Conditions: Respiratory Syncytial Virus Infection

Summary: the study was designed to gather information regarding the use of palivizumab for the prophylaxis for respiratory syncytial virus (rsv) infection in high-risk infants in selected countries within latin america.

rsv causes significant disease. there is a paucity of data from developing countries even though existing data clearly indicate that rsv accounts for a high proportion of acute respiratory illnesses (aris) in children. this is a multi-center study in a cohort of infants at risk for rsv infection in latin america who have received palivizumab in the usual manner in accordance with the terms of marketing authorization with regard to dose, population and indication. enrolled participants were followed for one year after their first dose of palivizumab. epidemiological and clinical data as well as information about compliance, hospitalizations and safety was collected.

Eligibility criteria:
inclusion criteria: * children with a history of bronchopulmonary dysplasia, infants with a history of prematurity (less than or equal to 35 weeks gestational age), or children with hemodynamically significant congenital heart disease who received the first dose of palivizumab within the 2 weeks prior to the signature of the informed consent form. * parent or legal guardian of child provides written informed consent exclusion criteria: * children excluded from receiving palivizumab as per local guidelines

Keywords: palivizumab lower respiratory tract infection respiratory syncytial virus usage patterns
trial of a limited versus traditional oxygen strategy during resuscitation in premature newborns

Conditions: Prematurity; Oxidative Stress

Summary: preterm infants are born with immature lungs and often require help with breathing shortly after birth. this traditionally involves administering 100% oxygen. unfortunately, delivery of high oxygen concentrations leads to the production of free radicals that can injure many organ systems. term and near-term newborns deprived of oxygen during or prior to birth respond as well or better to resuscitation with room air (21% oxygen) compared to 100% oxygen. however, a static concentration of 21% oxygen may be inappropriate for preterm infants with lung disease.purpose of the study is to investigate if preterm neonates where resuscitation is initiated with 21% fio2 and adjusted to meet transitional goal saturations (limited oxygen strategy or lox) would have less oxidative stress as measured by the oxidative balance ratio of biological antioxidant potential/total hydroperoxide compared to infants where resuscitation is initiated with pure oxygen and titrated for targeted saturations of 85-94% (traditional oxygen strategy or tox). secondary outcomes of interest included need for other delivery room resuscitation measures, respiratory support and ventilation/oxygenation status upon neonatal intensive care unit (nicu) admission, survival to hospital discharge, bronchopulmonary dysplasia and other short-term morbidities.


Eligibility criteria:
inclusion criteria: * inborn * gestation age 24 0/7 to 34 6/7 * need for active resuscitation exclusion criteria: * prenatally diagnosed cyanotic congenital heart disease * non-viable newborns * precipitous delivery and resuscitation team not present in the delivery room to initiate resuscitation
non-inferiority of meningococcal vaccine gsk134612 versus mencevax™ in 2-10 year old subjects

Conditions: Infections, Meningococcal; Meningococcal Vaccines

Summary: the purpose of this study is to demonstrate, in 2-10 year old subjects, the non-inferiority of meningococcal vaccine gsk134612 compared to licensed meningococcal vaccine mencevax™. the protocol posting has been updated in order to comply with the fda amendment act, sep 2007.

multicentre study with 2 treatment groups. two blood samples will be taken, prior to and one month after vaccination, from the first 75% enrolled subjects per country independent of the treatment group.

Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that their parents or guardians can and will comply with the requirements of the protocol. * a male or female between, and including, 2 and 10 years of age at the time of vaccination. * written informed consent obtained from the parent or guardian of the subject. * free of obvious health problems as established by medical history and clinical examination before entering into the study. * previously completed routine childhood vaccinations to the best of his/her parents'/guardians' knowledge. exclusion criteria: * use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine. * previous vaccination with meningococcal polysaccharide vaccine of serogroup a, c, w-135 and/or y (for subjects below 6 years) or within the last five previous years (for subjects 6 years old or above). * previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroups a, c, w-135 and/or y. * previous vaccination with tetanus toxoid within the last month. * history of meningococcal disease. * any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (hiv) infection, based on medical history and physical examination.. * history of reactions or allergic disease likely to be exacerbated by any component of the vaccine(s). * major congenital defects or serious chronic illness. * acute disease at the time of enrolment. * administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

Keywords: safety meningococcal vaccine immunogenicity
evaluation of reds pro system v2.7 and reds icu in patients with heart failure

Conditions: Heart Failure

Summary: the study is an investigator-initiated, prospective cohort trial. the trial aims to evaluate reds pro system v2.7 and reds icu in patients with heart failure (hf).

the study is an investigator-initiated, prospective cohort trial. the trial aims to evaluate reds pro system v2.7 and reds icu in patients with heart failure (hf). the overall purposes are: * to evaluate the reds efficacy measurements of lung fluid compared to pulmonary artery pressure guided therapy with cardiomems in out-patients with hf. * to describe the feasibility of reds icu in patients admitted to an icu with hf for the out-patient part, the patients will be recruited from the outpatient clinic at rigshospitalet. the patient must be at least 18 years, have a history of chronic hf, and already monitored using cardiomems and must not fulfill any of the exclusion criteria. for the icu part, the patients will be recruited at the icu department at the heart center at rigshospitalet. the patient must be at least 18 years, intubated, and unconscious or sedated (glasgow coma score \<8), and already monitored using swan-ganz and arterial catherization and must not fulfill any of the exclusion criteria.

Eligibility criteria:
inclusion criteria: icu part: * at least 18 years of age * hospitalized in icu setting at rigshospitalet * intubated * unconscious or sedated (glasgow coma score \<8) * monitored using swan-ganz and arterial catherization. out-patient part: * at least 18 years of age * history of chronic heart failure \> 3 months * cardiomems exclusion criteria: icu part: * pacemaker or icd on the right side * congenital heart malformations or intra-thoracic mass that would affect the right lung anatomy (e.g. dextrocardia, lung carcinoma) * wounds, burns, healing tissue, skin infection or recent skin graft or flap where the sensors should be attached to the skin * habitus is out of range due to one or more of the following * height less than 155 cm or higher than 195 cm * estimated bmi of less than 22 or more than 36 * standard active therapy has been stopped as the patient is inevitably dying. out-patient part: * pacemaker or icd on the right side * congenital heart malformations or intra-thoracic mass that would affect the right lung anatomy (e.g. dextrocardia, lung carcinoma) * wounds, burns, healing tissue, skin infection or recent skin graft or flap where the sensors should be attached to the skin * habitus is out of range due to one or more of the following height less than 155 cm or higher than 195 cm bmi of less than 22 or more than 38 for bmi 36 to 38, chest size ruler should be 39 or less * cancer or other severe non-cardiac disease with estimated life expectancy less than 1 year * planned hospitalization for icd, pacemaker, lung or heart surgery including heart transplantation during the study period.
tpbm in older adults with traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: the purpose of this study is to evaluate the effect of transcranial photobiomodulation (tpbm) in older patients with chronic traumatic brain injury (tbi). the study aims to examine the effect of tpbm on prefrontal cerebral blood flow (cbf) and executive function (ef)


Eligibility criteria:
inclusion criteria: 1. able to give written informed consent and follow study procedures. 2. age ≥ 55 years and ≤ 85 years. 3. history of non-penetrating tbi of at least moderate severity, 1. defined by emergency department glasgow coma scale (gcs) \< 13, 2. or post-traumatic amnesia \> 24 hours, 3. or loss of consciousness \> 30 minutes, 4. or evidence of trauma-related abnormality on acute neuroimaging. 4. between 1 and 2 years post injury. exclusion criteria: 1. delayed loss of consciousness due to expanding lesions 2. diagnosis of dementia, history of brain tumor, or other serious neurological disorder 3. diagnostic and statistical manual of mental disorders (dsm)-5 diagnosis of alcohol or drug use disorder or history of other major psychiatric illness diagnosed with mini-international neuropsychiatric interview (mini) 4. history of significant cardiovascular or cerebrovascular pathology before sustaining tbi 5. unstable medical conditions or medications impacting cognition (e.g., topiramate) 6. significant skin conditions on the subject's scalp in the area of illumination 7. large bilateral prefrontal cortex (pfc) lesions (i.e., more than 50% of our middle frontal gyrus region of interest (roi) in both hemispheres) 8. claustrophobia or metallic foreign bodies that would preclude mri 9. unwilling/unable to comply with study as judged by the principal investigator 10. body mass index \> 40 kg/m2 to fit comfortably in mri 11. past intolerance or hypersensitivity to tpbm 12. any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment

Keywords: tbi
effect of yoga@work program

Conditions: Musculoskeletal Pain; Neck Pain; Shoulder Pain

Summary: employees working in it industry are prone to develop musculoskeletal pain,specifically back, neck and shoulder pain. this study evaluates the effectiveness of work-site yoga intervention, yoga@work on neck and shoulder pain in it employees.


Eligibility criteria:
inclusion criteria: * it companies employee * full time employment * neck and shoulder pain * pain of at least 3 months duration * able to comply with intervention schedule exclusion criteria: * pregnancy * refuse to give informed consent * spinal fracture * recent cervical spine or shoulder surgery * recent (3 months) chemotherapy/radiotherapy/ intervention
high dosage esomeprazole and baclofen for therapy of gastroesophageal reflux disease

Conditions: Patients With Persistent Objectified Gastroesophageal Reflux and Reflux-Associated Symptoms Despite PPI-Therapy With 40mg Esomeprazole

Summary: it has been reported that baclofen is an appropriate tool in the therapeutic management of gastroesophageal reflux disease. to objectify gastroesophageal reflux combined ph-metry/impedance monitoring was applied to patients with persistent reflux-associated symptoms despite ppi-therapy (40mg esomeprazole for 2 weeks). after provement of pathological findings in the test ppi-dosage was escalated to double standard-dosage for another for weeks. in case of persistent symptoms another ph-metry/impedance monitoring was performed. in case of pathological findings additional baclofen was administered to the therapeutic regime. after 3 months another ph-metry/impedance monitoring was performed. at the time point of the tests a questionnaire was completed. aim of the study was to evaluate the influence of high dosage ppi-therapy and additional baclofen in patients with persistent symptoms and objectified gastroesophageal reflux.


Eligibility criteria:
inclusion criteria: * age between 18-70 years * informed consent * patients with persistent reflux-associated symptoms despite ppi-therapy exclusion criteria: * epilepsy * synthetic liver diseases * renal failure * disability to understand informed consent

Keywords: gastroesophageal reflux disease baclofen impedance
glucose empowerment through monitoring and social support in pregnancy

Conditions: Pregnancy, Complications; Gestational Diabetes

Summary: the purpose of the research is to learn whether wearing a continuous glucose monitor that shows blood glucose levels in real time on a smart phone app and participating in a group chat with other research participants will help participants keep a healthy blood glucose level during pregnancy. high levels of blood glucose during pregnancy can lead to health problems during and after pregnancy. it may also increase the risk for health problems for the developing baby. the investigators think our program might be a new way to help some people maintain a healthy blood glucose level during pregnancy. when pregnant people know their blood glucose levels are high, they can do things like exercise or drink water to bring their blood glucose levels down. they can also learn what foods to eat to maintain healthy blood glucose levels, and what foods to avoid. the investigators think being in a group chat with other pregnant individuals will allow participants to support and learn from each other. pregnant individuals should also work with their healthcare providers to manage their blood glucose levels.


Eligibility criteria:
inclusion criteria: * pregnant (\<20w0d) * at least 18 years to 45 years old * bmi \>25, personal history of gdm, or first-degree family member with type ii diabetes * comfortable conversing in english * own a smartphone and willing to use the cgm app and signal * receiving prenatal care and planning to deliver at tufts medicine (boston) * signed the consent form * currently located in the united states exclusion criteria: * current pregnancy a multiple gestation (e.g., twins) * smoked during this current pregnancy * active hepatitis or hiv infection * current pregnancy have any documented fetal congenital anomalies * current history of heroin, cocaine, crack, lsd, or methamphetamines * current history of alcohol abuse * previous gastric bypass * shift work that alters the sleep/wake periods * have known rheumatological or chronic inflammatory state (i.e., arthritis, inflammatory bowel disease)? * chronic illnesses, including diabetes and dialysis, that require regular medication use * uncontrolled hypothyroidism * known culture of positive chorioamnionitis? * an adult who is unable to consent (e.g., cognitively impaired adults) * ward of the state * unable to read or write english

Keywords: pregnancy gestational diabetes gdm intervention hyperglycemia group chat continuous glucose monitoring mobile-based behavioral change cgm